Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Séverine Blesson
Observed names:
S Blesson,
S. Blesson,
Severine Blesson
Institution:
Drugs for Neglected Diseases Initiative
Observed institutions:
Université de Tours,
Seton Hall University,
Drugs for Neglected Diseases Initiative,
Inserm,
Institut Gustave Roussy
ORCID:
0000-0002-3007-8015
Observed ORCID:
0000-0002-3007-8015
OpenAlex ID:
A5076945656
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial
2017
·
Victor Kande Betu Ku Mesu
, Wilfried Mutombo Kalonji
, et al.
·
The Lancet
·
291
PDF
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
2018
·
Fabiana Alves
, Graeme Bilbe
, et al.
·
Clinical Microbiology Reviews
·
220
Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies
2014
·
Antoine Tarral
, Séverine Blesson
, et al.
·
Clinical Pharmacokinetics
·
107
PDF
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
2019
·
Ermias Diro
, Severine Blesson
, et al.
·
PLoS neglected tropical diseases
·
88
PDF
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
2021
·
Victor Kande Betu Ku Mesu
, Wilfried Mutombo Kalonji
, et al.
·
The Lancet Global Health
·
59
PDF
In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness
2012
·
Caecilia Schmid
, Andrea Kuemmerle
, et al.
·
PLoS neglected tropical diseases
·
57
PDF
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
2019
·
Ermias Diro
, Tansy Edwards
, et al.
·
PLoS neglected tropical diseases
·
42
Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study
2023
·
Antoine Tarral
, Lionel Hovsepian
, et al.
·
Clinical Pharmacokinetics
·
37
PDF
Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO
2002
·
S. Blesson
, J. Thiery
, et al.
·
International Immunology
·
37
Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study
2021
·
Andrea Kuemmerle
, Caecilia Schmid
, et al.
·
PLoS neglected tropical diseases
·
35
PDF
Host Transcriptomic Signature as Alternative Test-of-Cure in Visceral Leishmaniasis Patients Coinfected with HIV
2020
·
Wim Adriaensen
, Bart Cuypers
, et al.
·
EBioMedicine
·
27
PDF
Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
2016
·
A. E. Kip
, H. Rosing
, et al.
·
Antimicrobial Agents and Chemotherapy
·
22
PDF
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
2022
·
Victor Kande Betu Kumesu
, Wilfried Mutombo Kalonji
, et al.
·
The Lancet Global Health
·
20
The anti-angiogenic activity of IL-12 is increased in iNOS−/− mice and involves NK cells
2010
·
Aleksandra Bielawska-Pohl
, Séverine Blesson
, et al.
·
Journal of Molecular Medicine
·
20
Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
2021
·
Anke E Kip
, Séverine Blesson
, et al.
·
Journal of Antimicrobial Chemotherapy
·
13
PDF
Improving the Quality of Host Country Ethical Oversight of International Research: The Use of a Collaborative ‘Pre‐Review’ Mechanism for a Study of Fexinidazole for Human A frican Trypanosomiasis
2014
·
Carl H. Coleman
, Chantal Ardiot
, et al.
·
Developing World Bioethics
·
12
PDF
A DBS Method for Quantitation of The New Oral Trypanocidal Drug Fexinidazole and its Active Metabolites
2016
·
Aziz Filali-Ansary
, Cécile Augé
, et al.
·
Bioanalysis
·
6
Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
2025
·
Jean‐Yves Gillon
, Sophie Delhomme
, et al.
·
British Journal of Clinical Pharmacology
·
4
PDF
[Hemolytic anemia after kidney transplantation].
1994
·
J Cartron
, S Blesson
, et al.
·
PubMed
·
3
Study of first dosing of a new compound DNDi-6148 in healthy volunteers to assess safety and drug levels in blood and urine after escalating single dose
2020
·
Severine Blesson
·
http://isrctn.com/
·
1
Population pharmacokinetics of DNDI-6148 in healthy adults
2026
·
Frauke Assmus
, Ayorinde Adehin
, et al.
·
PLoS neglected tropical diseases
PDF
Study to test the safety and tolerability of a new drug (DNDI-0690) in healthy subjects
2023
·
Severine Blesson
·
http://isrctn.com/
A study to assess the safety, drug levels in blood and markers of immune system response in patients after multiple doses of a new compound developed for the treatment of cutaneous leishmaniasis, CpG-ODN-D35
2022
·
Severine Blesson
·
http://isrctn.com/
A study to assess safety, drug levels in blood and markers of immune system response after an escalating single dose of a new compound developed for the treatment of cutaneous leishmaniasis, CpG-ODN-D35, in healthy male subjects
2021
·
Severine Blesson
·
http://isrctn.com/
A study to investigate the safety, tolerability and activity of multiple ascending doses of DNDI-0690 in healthy volunteers including assessment of heart and kidney function
2021
·
Severine Blesson
·
http://isrctn.com/
Show more works
View as search
Works count:
29
Citation count:
1,101
H-index:
14
I10-index:
16
Year
Topic
Type
